Roche’s Tecentriq is now the first immunotherapy drug approved by the FDA for the treatment of breast cancer.
Tecentriq, to be given with chemotherapy, was approved for treating advanced triple-negative breast cancer, which accounts for about 15 percent of cases.
In a trial of 900 women, those who received Tecentriq plus chemo went two months longer on average without their cancer worsening compared with those on chemo alone.
Read the press release.
